Triple-negative breast cancer—current status and future directions von Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., Harbeck, N.

Volltext

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks... von Nitz, U A, Gluz, O, Christgen, M, Grischke, E-M, Augustin, D, Kuemmel, S, Braun, M, Potenberg, J, Kohls, A, Krauss, K, Stefek, A, Schumacher, C, Forstbauer, H, Reimer, T, Fischer, H, Liedtke, C, Wuerstlein, R, Schumacher, J, Kates, R, Kreipe, H, Harbeck, N

Volltext

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endo... von Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., Schmidt, M., Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard

Volltext

Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2− early breast cancer: results from th... von Gluz, O., Kuemmel, S., Nitz, U., Braun, M., Lüdtke-Heckenkamp, K., von Schumann, R., Darsow, M., Forstbauer, H., Potenberg, J., Uleer, C., Grischke, E.M., Aktas, B., Schumacher, C., zu Eulenburg, C., Kates, R., Jóźwiak, K., Graeser, M., Wuerstlein, R., Baehner, R., Christgen, M., Kreipe, H.H., Harbeck, N.

Volltext

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression von Nitz, U., Gluz, O., Huober, J., Kreipe, H.H., Kates, R.E., Hartmann, A., Erber, R., Scholz, M., Lisboa, B., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Weiss, E., Böhmer, S., Kreienberg, R., Du Bois, A., Sattler, D., Thomssen, C., Kiechle, M., Jänicke, F., Wallwiener, D., Harbeck, N., Kuhn, W.

Volltext

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study von Wuerstlein, R., Kates, R., Gluz, O., Grischke, E. M., Schem, C., Thill, M., Hasmueller, S., Köhler, A., Otremba, B., Griesinger, F., Schindlbeck, C., Trojan, A., Otto, F., Knauer, M., Pusch, R., Harbeck, N.

Volltext

Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive mark... von Nitz, U.A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.

Volltext

Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients von Wuerstlein, R., Harbeck, N., Grischke, E.-M., Forstmeyer, D., von Schumann, R., Krabisch, P., Nitz, U., Gluz, O., Kates, R.E., Graeser, M.

Volltext

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial von Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H., Metzner, B., Werner, F., Schütt, G., Frick, M., Poremba, C., Diallo-Danebrock, R., Mohrmann, S.

Volltext

Prognostic impact of anthracyclines and immune/proliferation markers in TNBC according to pCR after de-escalated neoadjuvant chemotherapy with 12 weeks of nab-paclitaxel/carboplati... von Gluz, O., Nitz, U., Liedtke, C., Christgen, M., Grischke, E.-M., Forstbauer, H., Braun, M., Warm, M., Hackmann, J., Uleer, C., Aktas, B., Schumacher, C., Lindner, C., Kümmel, S., Kates, R.E., Potenberg, J., Staib, P., Wuerstlein, R., Kreipe, H.H., Harbeck, N.

Volltext

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial von Gluz, O., Liedtke, C., Huober, J., Peyro-Saint-Paul, H., Kates, R.E., Kreipe, H.H., Hartmann, A., Pelz, E., Erber, R., Mohrmann, S., Möbus, V., Augustin, D., Hoffmann, G., Thomssen, C., Jänicke, F., Kiechle, M., Wallwiener, D., Kuhn, W., Nitz, U., Harbeck, N.

Volltext

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression von Nitz, U, Gluz, O, Huober, J, Kreipe, H H, Kates, R E, Hartmann, A, Erber, R, Moustafa, Z, Scholz, M, Lisboa, B, Mohrmann, S, Möbus, V, Augustin, D, Hoffmann, G, Weiss, E, Böhmer, S, Kreienberg, R, Du Bois, A, Sattler, D, Thomssen, C, Kiechle, M, Jänicke, F, Wallwiener, D, Harbeck, N, Kuhn, W

Volltext

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 ex... von Nitz, U, Gluz, O, Huober, J, Kreipe, H H, Kates, R E, Hartmann, A, Erber, R, Moustafa, Z, Scholz, M, Lisboa, B, Mohrmann, S, Möbus, V, Augustin, D, Hoffmann, G, Weiss, E, Böhmer, S, Kreienberg, R, Du Bois, A, Sattler, D, Thomssen, C, Kiechle, M, Jänicke, F, Wallwiener, D, Harbeck, N, Kuhn, W

Volltext

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks... von Nitz, U.A., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.

Volltext

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer von Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Dünnebacke, J., Belzl, N., Augustin, D., Kates, R.E., Harbeck, N.

Volltext

Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with... von Gluz, O, Nitz, U, Christgen, M, Kates, R, Clemens, M, Nuding, B, Shak, S, Würstlein, R, Kreipe, H, Harbeck, N

Volltext

Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay von Mamounas, E.P, Goldstein, L.J, Penault-Llorca, F, Roché, H, Gluz, O, Harbeck, N, Nitz, U, O’shaughnessy, J, Albain, K.S

Volltext

Impact of MammaPrint and BluePrint on early breast cancer treatment decisions: WSG PRIMe study results von Wuerstlein, R, Grischke, E.M, Gluz, O, Kates, R, Persoon, M, Thill, M, Hasmueller, S, Knauer, M, Pusch, R, Harbeck, N

Volltext

1937 Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial von Gluz, O, Nitz, U, Kreipe, H.H, Christgen, M, Kates, R.E, Hofmann, D, Shak, S, Clemens, M, Kraemer, S, Aktas, B, Kuemmel, S, Reimer, T, Kusche, M, Heyl, V, Lorenz-Salehi, F, Just, M, Liedtke, C, Wuerstlein, R, Harbeck, N

Volltext

P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study von Gluz, O, Nitz, U, Christgen, M, Kreipe, H, Kates, R.E, Kuemmel, S, Braun, M, Schumacher, C, Wuerstlein, R, Harbeck, N

Volltext